---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Cost assumptions"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Cost assumptions. Topics: Medicare Part B payment limits for parenteral comparators and bone-targeted agents, October to December 2026; Radium-223 dichloride: payment limit note in the Medicare Part B file; Hospital outpatient payment rates for radiopharmaceuticals, October 2026; Lutetium Lu 177 vipivotide tetraxetan: per-dose cost estimated from Medicare Administrative Contractor payment rates; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics/cost-assumptions"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Cost assumptions

<a id="heading-4.2.4"></a>

## 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

### Medicare Part B payment limits for parenteral comparators and bone-targeted agents, October to December 2026

> “Effective October 1, 2026 through December 31, 2026”
> “Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data.”

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
| --- | --- | --- | --- | --- |
| J9043 cabazitaxel (Jevtana) | “Cabazitaxel injection” | “1 MG” | “231.688” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| Q2043 sipuleucel-T (Provenge) | “Sipuleucel-t auto cd54+” | “Per infusion (minimum 50 million cells)” | “55663.131” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J0897 denosumab (Xgeva) | “Denosumab injection” | “1 MG” | “29.856” | “17.885” |
| J3489 zoledronic acid | “Zoledronic acid 1mg” | “1 MG” | “17.673” | “20.000” |
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1 microCurie” | “N/A” | “20.000” |

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-2"></a>

### Radium-223 dichloride: payment limit note in the Medicare Part B file

> “microCurie 100% AWP = $212.84”
> “microCurie 100% WAC = $177.37”

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-3"></a>

### Hospital outpatient payment rates for radiopharmaceuticals, October 2026

| HCPCS code and product | Short descriptor | APC | Payment rate | Minimum unadjusted copayment |
| --- | --- | --- | --- | --- |
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1745” | “$180.422” | “$36.09” |
| A9607 lutetium Lu 177 vipivotide tetraxetan (Pluvicto) | “Lutetium lu 177 vipivotide” | “9054” | “$266.541” | “$53.31” |

Source: [CMS OPPS Addendum B (2026)](https://www.cms.gov/files/zip/October-2026-OPPS-Addendum-B.zip)

<a id="topic-4.2.4-4"></a>

### Lutetium Lu 177 vipivotide tetraxetan: per-dose cost estimated from Medicare Administrative Contractor payment rates

> “We collected all identifiable MAC payment rates for 177Lu-PSMA-617 (HCPCS A9607) across publicly available MAC jurisdictions (JE, JF, JJ, JM, J6, JK, and J15), standardized rates to a per-millicurie basis, and used the median to reduce outlier influence. Assuming the use of a 200-mCi dose, this yielded an estimated per-dose cost of $55,522 (3).”
> “Although 177Lu-PSMA-617 was approved by the Food and Drug Administration in March 2022 (7), there remains no ASP-based benchmark for this agent within the CMS ASP framework; under the current reimbursement structure, such a benchmark would not be expected to emerge absent U.S. legislative or regulatory change (4–6).”

Source: [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/)

<a id="topic-4.2.4-5"></a>

### Per-cycle costs in the U.S. lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model

| Input | Base case value (USD) | Range for sensitivity analysis (USD) |
| --- | --- | --- |
| Cost per cycle, lutetium Lu 177 vipivotide tetraxetan | “32,062” | “25,649–38,474” |
| Cost per cycle, cabazitaxel | “14,382” | “11,505–17,852” |
| Gallium Ga 68 PSMA PET/CT | “5,689” | “4,551–6,829” |
| End of life | “17,312” | “13,849–20,773” |

Source: [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/)

<a id="topic-4.2.4-6"></a>

### Darolutamide wholesale acquisition cost

| Product and package | Manufacturer | Drug product description | WAC effective date | WAC increase amount (USD) | WAC after increase (USD) |
| --- | --- | --- | --- | --- | --- |
| Nubeqa (darolutamide) 300 mg, 120 tablets | “Bayer” | “Nubeqa 300 mg tab 120 count” | “2026-01-01T00:00:00” | “847.20” | “15100.80” |

Source: [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27)

<a id="topic-4.2.4-7"></a>

### Enzalutamide: Medicare negotiated price effective January 2027 and 2024 list price

| Drug | Participating drug company | Agreed to negotiated price for 30-day supply for CY 2027 | List price for 30-day supply, CY 2024 | Discount of negotiated price from 2024 list price |
| --- | --- | --- | --- | --- |
| Xtandi (enzalutamide) | “Astellas Pharma US, Inc.” | “$7,004” | “$13,480” | “48%” |

Source: [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)

> “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies.”
> “List prices are rounded to the nearest dollar and represent the Wholesale Acquisition Costs (WACs) for the selected drugs based on 30-day supply using CY 2024 prescription fills.”

Source: [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)

<a id="topic-4.2.4-8"></a>

### Company price assumption in the post-abiraterone addressable market estimate

> “Post-abiraterone mCRPC is a significant unmet need and commercial opportunity, representing a $3.5bn total addressable market annually in the US with lack of oral and well-tolerated therapies”
> “Note: Addressable market assumes current price of ARPIs for illustrative purposes.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
